Viking Therapeutics, Inc. (VKTX)

(A Top Pick Mar 02/21, Down 29.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with VKTX has triggered its stop loss at $6.50. To remain disciplined, we recommend covering the position at this time. We will look for better opportunities.

Stockchase Research Editor: Michael O'Reilly VKTX is a pharma company that develops treatments for things such as fatty liver disease, type 2 diabetes and kidney disease to name a few. There are some promising products in development. The company has over 54% of its shares owned by institutions -- signaling key staying power. Analysts expect EPS growth over the next 5 years of 40% annually. We would buy this with a stop-loss at $6.50, looking to target $14.00 - upside potential over 47%. Yield 0% (Analysts’ price target is $14.00)